MIRM Stock: Price, Forecast, Financials & AI Analysis

High

93.700

Open

93.700

VWAP

91.90

Vol

336.13K

Mkt Cap

4.71B

Low

90.860

Amount

30.89M

EV/EBITDA(TTM)

Total Shares

51.68M

4.64B

EV/OCF(TTM)

103.81

P/S(TTM)

9.83

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Events Timeline

(ET)

2026-01-12

09:20:00

Bluejay Therapeutics AZURE-1 Study Interim Data Expected Q2 2026

2026-01-12

09:20:00

Mirum Reports Preliminary FY25 Revenue of $520M

News

5.0

01-13NASDAQ.COM

Meta Platforms Launches AI Glasses with 3.54 Billion Daily Users

5.0

01-13Fool

Meta, Micron, and Mirum: Top Growth Stocks for 2026

5.0

01-12Businesswire

Mirum Pharmaceuticals Grants 4,900 Stock Options and 6,500 RSUs to New Employees

5.0

01-12Fool

Mirum Pharmaceuticals Director Exercises 5,000 Options, Totaling $400,000 in Transactions

5.0

01-04NASDAQ.COM

Small-Cap and Renewable Energy Stocks Expected to Perform Well in 2026

5.0

01-04Fool

2026 Stock Market Predictions: Small-Cap Stocks to Rise

9 Analyst Rating

Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 88.11 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

77.00

Averages

88.11

High

95.00

Current: 0.000

Low

77.00

Averages

88.11

High

95.00

Citizens

Jonathan Wolleben

Outperform

maintain

$95 -> $140

Al Analysis

2025-12-19

Reason

Citizens

Jonathan Wolleben

Price Target

$95 -> $140

Al Analysis

2025-12-19

maintain

Outperform

Reason

Citizens analyst Jonathan Wolleben raised the firm's price target on Mirum Pharmaceuticals to $140 from $95 and keeps an Outperform rating on the shares. Mirum has outperformed year to date and is expected to continue leading in 2026, supported by multiple high-confidence pivotal readouts across its pipeline, the analyst tells investors in a research note. The brelovitug acquisition adds a late-stage asset with near-term data, while volixibat's pivotal readout in 2Q26 for primary sclerosing cholangitis drives increased confidence and a higher probability of success, the firm says.

Leerink

Outperform

maintain

$90 -> $100

2025-12-10

Reason

Leerink

Price Target

$90 -> $100

2025-12-10

maintain

Outperform

Reason

Leerink raised the firm's price target on Mirum Pharmaceuticals to $100 from $90 and keeps an Outperform rating on the shares. The firm updated its Mirum model for the Bluejay acquisition terms and concurrent Private Investment in Public Equity, both expected to close in Q1. Meanwhile, clinical development and commercialization of brelovitug is expected to require about $250M over the next two years, and Mirum will pay up to $200M in tiered sales milestones, the analyst tells investors in a research note. Following encouraging Phase 2 ddata for brelovitug for the treatment of chronic hepatitis delta, Phase 3 interim data is expected in 2Q26 and topline results in 2H26, the analyst adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MIRM

Unlock Now

Valuation Metrics

The current forward P/E ratio for Mirum Pharmaceuticals Inc (MIRM.O) is -306.16, compared to its 5-year average forward P/E of -18.64. For a more detailed relative valuation and DCF analysis to assess Mirum Pharmaceuticals Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.64

Current PE

-306.16

Overvalued PE

144.03

Undervalued PE

-181.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.42

Current EV/EBITDA

63.42

Overvalued EV/EBITDA

60.10

Undervalued EV/EBITDA

-86.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.52

Current PS

6.96

Overvalued PS

9.34

Undervalued PS

3.70

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Mirum Pharmaceuticals Inc (MIRM) stock price today?

The current price of MIRM is 91.05 USD — it has decreased -1.38 % in the last trading day.

What is Mirum Pharmaceuticals Inc (MIRM)'s business?

What is the price predicton of MIRM Stock?

Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is88.11 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Mirum Pharmaceuticals Inc (MIRM)'s revenue for the last quarter?

Mirum Pharmaceuticals Inc revenue for the last quarter amounts to 133.01M USD, increased 47.17 % YoY.

What is Mirum Pharmaceuticals Inc (MIRM)'s earnings per share (EPS) for the last quarter?

Mirum Pharmaceuticals Inc. EPS for the last quarter amounts to 0.05 USD, decreased -116.67 % YoY.

How many employees does Mirum Pharmaceuticals Inc (MIRM). have?

Mirum Pharmaceuticals Inc (MIRM) has 322 emplpoyees as of January 18 2026.

What is Mirum Pharmaceuticals Inc (MIRM) market cap?

Today MIRM has the market capitalization of 4.71B USD.

MIRM Overview

MIRM Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

People Also Watch

Frequently Asked Questions

What is Mirum Pharmaceuticals Inc (MIRM) stock price today?

What is Mirum Pharmaceuticals Inc (MIRM)'s business?

What is the price predicton of MIRM Stock?

What is Mirum Pharmaceuticals Inc (MIRM)'s revenue for the last quarter?

What is Mirum Pharmaceuticals Inc (MIRM)'s earnings per share (EPS) for the last quarter?

How many employees does Mirum Pharmaceuticals Inc (MIRM). have?

What is Mirum Pharmaceuticals Inc (MIRM) market cap?